Rheumatoid Arthritis

Rheumatoid arthritis is rated under 38 CFR § 4.71a, diagnostic code 5002, and it does not work like the joint codes most veterans expect. DC 5002 runs on two parallel tracks. One track rates the disease as an active inflammatory process based on systemic impairment, exacerbation frequency, and constitutional symptoms. The other track rates the chronic residuals once the disease has gone inactive, based on limitation of motion or ankylosis of the joints it damaged. The single most important rule in the whole code is that you do not combine the two. You assign the higher.

That structure is where most RA claims go sideways. Rheumatoid arthritis is a systemic, symmetric autoimmune disease. It attacks joints on both sides of the body, it flares and remits, and it shows up in bloodwork long before it shows up on an X-ray. The rating examiner has to capture all of that: the serologic markers, the inflammatory markers, the medication regimen, the exacerbation history, and the joint damage that's accumulated over time. When the exam captures only a snapshot of today's joint motion, the active-process rating collapses and the veteran gets rated as if the disease were a quiet case of osteoarthritis.

The dataset shows how often that happens. In Claim Raven's analysis of 505 BVA rheumatoid arthritis cases, the C&P exam was flagged as inadequate in 74.4% of the cases where adequacy could be assessed. That is the highest C&P-inadequate share of any condition I analyzed, and it pairs with one of the highest remand shares in the set. This page walks through DC 5002's two tracks, the active-process tiers, the chronic-residual fallback, what a competent C&P exam has to measure, the medication-driven secondary chains under § 3.310, and why the exam-quality problem dominates RA outcomes at the Board.

TL;DR

• Rheumatoid arthritis is rated under 38 CFR § 4.71a, DC 5002, on two separate tracks: the disease as an active process, or the chronic residuals once it goes inactive.
• The active-process tiers run 100%, 60%, 40%, and 20%, driven by constitutional symptoms, weight loss and anemia, severity of health impairment, and the frequency of incapacitating exacerbations.
• The chronic-residual track rates limitation of motion or ankylosis of the affected joints under the appropriate joint codes when the disease is inactive.
• The active-process rating and the residual rating are not combined. The rater assigns the higher of the two. That is the rule veterans most often need enforced.
• RA is systemic and symmetric, so documentation of serologic markers (RF, anti-CCP), inflammatory markers (ESR, CRP), DMARD or biologic therapy, and exacerbation frequency drives the active-process rating.
• The medications used to control RA open a secondary chain under 38 CFR § 3.310: corticosteroids and immunosuppressants cause downstream conditions, and RA itself produces organ involvement.
• In Claim Raven's analysis of 505 BVA rheumatoid arthritis cases, 64 were granted (12.7%), 279 were remanded (55.2%), and 133 were denied (26.3%).
• Of the 332 RA cases with a C&P adequacy determination, 74.4% had the exam flagged as inadequate, the highest C&P-inadequate share of any condition I analyzed. The remand share is among the highest in the set, and the two facts are connected.

DC 5002: Two Tracks, One Rule

DC 5002 covers rheumatoid arthritis as an active process. Unlike the knee or shoulder codes, which rate a single mechanical impairment, DC 5002 has to account for a disease that moves through the body and changes over time. The regulation handles that by splitting the rating into two tracks.

The first track rates the disease while it is an active inflammatory process. This is the systemic rating. It looks at constitutional manifestations, the severity of impairment to overall health, and how often and how badly the veteran has incapacitating exacerbations.

The second track applies once the disease becomes inactive. At that point there's no active inflammation to rate, but the joints carry permanent damage. The residual track rates limitation of motion or ankylosis of the affected joints under the appropriate joint codes, the same way any other joint damage would be rated.

The rule that ties them together is the one veterans most need to understand:

Ratings for the active process will not be combined with the residual ratings for limitation of motion or ankylosis. Assign the higher evaluation.

You do not add the active-process number to the residual number. You compare them and take the larger one. That matters in both directions. A veteran with severe joint damage but a currently quiet disease should be rated on residuals if that produces the higher figure. A veteran with relatively preserved motion but a severely active disease with frequent incapacitating flares should be rated on the active process. The rater's job is to evaluate both and pick the higher. The error I see most often is a rater evaluating only one track, usually the residual joint motion, and never reaching the active-process analysis at all.

The Active-Process Tiers and What Each One Pays

The active-process side of DC 5002 has four compensable tiers. Each one keys off systemic impairment and exacerbation frequency rather than a goniometer reading.

100%. With constitutional manifestations associated with active joint involvement, totally incapacitating. This is the top of the code. It describes a veteran whose disease is both systemically active and disabling to the point of total incapacity.

60%. Weight loss and anemia productive of severe impairment of health, or severely incapacitating exacerbations four or more times a year, or a lesser number over prolonged periods. Two paths to 60%. One is the constitutional path, weight loss and anemia producing severe health impairment. The other is the exacerbation path, four or more severely incapacitating flares a year, or fewer flares that run for prolonged periods.

40%. Symptom combinations productive of definite impairment of health objectively supported by examination findings, or incapacitating exacerbations occurring three or more times a year. The key words here are "definite impairment of health" and "objectively supported by examination findings." This tier requires the exam to actually document the objective findings, which is exactly where RA exams tend to fall short.

20%. One or two exacerbations a year in a well-established diagnosis. The entry tier. It requires a well-established diagnosis and at least one or two exacerbations in a year.

The architecture of these tiers tells you what evidence drives the rating. The difference between 20%, 40%, and 60% on the active-process side is largely a question of how many incapacitating exacerbations the veteran has per year and how severely the disease impairs overall health. Those are facts that have to be documented over time, not measured in a single clinic visit. An exam that records today's joint exam and stops has no way to establish whether the veteran had three incapacitating flares last year or none.

The Chronic-Residual Track

When the rheumatoid disease becomes inactive, the active-process tiers stop applying because there is no active inflammation to rate. The residual track then rates the permanent joint damage the disease left behind.

The residuals are rated on limitation of motion or ankylosis of the affected joints under the appropriate diagnostic codes. A veteran whose RA damaged the knees rates the residual knee limitation under the knee codes. RA that damaged the wrists rates under the wrist codes. RA that fused a joint rates the ankylosis. Because RA is symmetric, the residuals are usually bilateral, which means the bilateral factor under 38 CFR § 4.26 often comes into play once the residuals are rated on paired extremities.

The residual track also interacts with the limitation-of-motion floor in DC 5003. Where RA has produced X-ray-confirmed joint involvement but motion is not yet limited enough for a compensable rating under the joint code, the residuals can pick up the minimum compensable rating that DC 5003 provides for X-ray-documented involvement of major joint groups. The point is that inactive RA is not a zero. The joints carry the disease's history, and that history is ratable.

The reason the "assign the higher" rule matters so much is that a veteran can move between the two tracks over the life of the claim. During an active phase, the active-process rating may be higher. During a quiet phase with significant accumulated damage, the residual rating may be higher. A well-built record lets the rater see both and assign whichever is larger at any given time.

C&P Exam Mechanics: What a Competent RA Exam Has to Capture

This is the heart of the RA rating problem, and it is where the dataset is loudest. An RA exam is not a range-of-motion exam with an autoimmune label. To support DC 5002, the examiner has to document the disease as a system, not just the joints as mechanics.

A competent rheumatoid arthritis exam should capture:

• Serologic markers. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. These confirm the diagnosis and distinguish RA from osteoarthritis. A "well-established diagnosis," which the 20% tier requires, is built on this.
• Inflammatory markers. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). These track disease activity and corroborate whether the process is active or inactive, which decides which track applies.
• Medication regimen. Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, and biologic agents. The treatment a veteran is on is itself evidence of disease severity and activity, and it opens the secondary chain discussed below.
• Exacerbation history. How many incapacitating exacerbations the veteran has had in the past year, how long they lasted, and how severely they impaired function. This is the single most important fact for the active-process tiers and the one most often missing.
• Constitutional symptoms. Weight loss, anemia, fatigue, and overall impairment of health. The 60% and 100% tiers turn on these.
• Joint involvement, bilateral and symmetric. Which joints are affected, on both sides, with range of motion and any ankylosis documented for the residual analysis.

When all of this is in the report, the rater has what's needed to evaluate both tracks and assign the higher. When the exam reduces RA to a single day's joint measurements, the active-process tiers have nothing to attach to, and the systemic disease gets rated as if it were mechanical joint wear. That is the failure pattern the 74.4% inadequacy figure is measuring.

Why RA Exams Get Flagged Inadequate So Often

The 74.4% C&P-inadequate share is the highest in any condition I analyzed, and it is not random. It tracks the structural mismatch between how DC 5002 is written and how a routine joint exam is conducted.

A standard musculoskeletal C&P exam is built to measure motion. It uses a goniometer, records flexion and extension, tests repetitive use, and notes pain. For a knee or a shoulder, that captures most of what the rating needs. For rheumatoid arthritis, it captures only the residual track and misses the active-process track entirely.

The active-process tiers ask questions a motion exam does not answer. How many incapacitating exacerbations per year? Is there weight loss and anemia producing severe impairment of health? Are the symptom combinations objectively supported by examination findings? An examiner who measures joint motion and writes "no flare observed today" has not addressed any of those questions. The Board then reads the exam, sees that it never reached the active-process analysis, and finds it inadequate for rating purposes.

That is the engine behind the remand share. With 279 of 505 cases remanded (55.2%), the Board is sending RA cases back for more development more often than it is granting or denying them. An inadequate exam is the most common reason an increased-rating or service-connection claim cannot be decided on the record, so it gets remanded for a new exam that actually addresses DC 5002's criteria. The exam-quality problem and the remand problem are the same problem viewed from two angles.

Documenting Exacerbations: The Active-Process Evidence Veterans Control

Because the active-process tiers turn on exacerbation frequency and severity, and because the C&P exam captures one day, the evidence the veteran builds outside the exam often decides the rating. The exam can confirm the diagnosis and current activity, but it cannot reconstruct a year of flares the examiner never saw.

The records that fill that gap:

• A symptom journal tracking each flare with dates, which joints were involved, how long the flare lasted, and whether the veteran could work or function during it.
• Documentation of incapacitating episodes: days bedridden, days unable to work, emergency or urgent care visits, steroid bursts prescribed to break a flare.
• Treatment records showing DMARD and biologic history, dose escalations, and switches between agents, which corroborate disease activity and severity.
• Lab trends over time showing ESR, CRP, RF, and anti-CCP values, which establish both the diagnosis and the activity level.
• Records of weight loss and anemia where present, which feed the 60% constitutional path.
• Statements from spouses, coworkers, or supervisors describing the veteran's function during active phases.

This is the RA analog of the flare-up documentation that drives knee and back claims. The difference is that for RA the exacerbation history is not a supplement to a motion rating, it is the substance of the active-process rating itself. Without it, the rater has no factual basis to reach 40% or 60%, and the claim defaults to the residual motion rating or to the 20% entry tier.

Secondary Chains: Medications and Organ Involvement

Rheumatoid arthritis opens a wide secondary chain under 38 CFR § 3.310, and the medications used to control it are a major driver. Secondary service connection can be granted for a condition caused by a service-connected condition or aggravated by one (Allen v. Brown).

Medication-driven secondaries. RA is treated with long-term corticosteroids and immunosuppressants, and those drugs cause their own conditions. Chronic corticosteroid use is associated with conditions such as osteoporosis, cataracts, glaucoma, and metabolic effects including weight and glucose changes. Immunosuppressant therapy carries its own downstream effects. When a service-connected RA requires the medication, and the medication causes the new condition, the new condition can be claimed as secondary. The nexus opinion has to identify the drug, the documented exposure, and the mechanism.

Organ and systemic involvement. RA is systemic, not joint-limited. It can affect the eyes, the lungs, and other organs as part of the disease process itself. Where the medical record documents RA-related involvement of another body system, that involvement can be service-connected as part of, or secondary to, the rheumatoid disease.

Functional secondaries. As with any orthopedic condition that alters gait or use patterns, RA-damaged joints can drive compensatory stress and downstream musculoskeletal claims, though the symmetric nature of RA makes the one-sided compensation chains less typical than they are for a single damaged knee.

For any of these chains, the standard is the same. A bare assertion that "the condition is related to the veteran's RA" is not probative. The opinion has to identify the mechanism, address the time course, and account for other causes. A fully articulated medical opinion based on sound reasoning carries the chain. A conclusory one does not.

Common Evidence Gaps in Rheumatoid Arthritis Claims

A few patterns I've noticed across BVA decisions involving rheumatoid arthritis.

The exam measures motion and never reaches the active process. This is the dominant gap and the one the 74.4% inadequacy figure is built on. The examiner runs a standard joint exam, records range of motion, and never documents exacerbation frequency, constitutional symptoms, or systemic disease activity. The rater is then stuck on the residual track and the active-process tiers go unaddressed.

No exacerbation history in the record. The active-process tiers turn on how many incapacitating flares the veteran has per year. When neither the exam nor the treatment records quantify the flares, the rater cannot reach 40% or 60% and defaults to the 20% entry tier or to residuals.

Serologic and inflammatory labs missing or stale. RF, anti-CCP, ESR, and CRP confirm the diagnosis and establish whether the disease is active. Without current labs, the "well-established diagnosis" requirement at 20% can be questioned, and the active-versus-inactive determination that decides which track applies has no objective anchor.

Medication regimen not documented as evidence. The DMARD and biologic history is evidence of disease severity and the trigger for the medication-secondary chain. When the record does not lay out what the veteran is taking and why, the rater loses both a severity signal and a secondary-claim pathway.

Residuals undervalued during quiet phases. When the disease is inactive, raters sometimes treat the claim as resolved rather than rating the accumulated joint damage on the residual track. Inactive RA still leaves ratable limitation of motion and, in some joints, ankylosis.

I don't know the exact percentage of RA claims that carry any one of these gaps. What I can say from Claim Raven's analysis of 505 BVA rheumatoid arthritis cases is that 74.4% of the cases with a C&P adequacy determination had the exam flagged as inadequate, the highest such share in the conditions I analyzed, and that remands ran at 55.2%, among the highest in the set. Those two numbers describe the same dynamic. The Board is repeatedly sending RA cases back because the exam of record never captured the systemic disease the rating code is built around. The cases that succeed tend to have a record that documents RA as a system: labs, medications, exacerbation history, and constitutional symptoms, not just a single day's joint motion.

Bottom Line

Rheumatoid arthritis ratings are not a single joint number. DC 5002 runs on two tracks: the disease as an active inflammatory process, rated on constitutional symptoms and exacerbation frequency at 20%, 40%, 60%, and 100%, and the chronic residuals once the disease goes inactive, rated on limitation of motion or ankylosis of the damaged joints. You do not combine the tracks. You assign the higher. The reason RA claims fail so often is the exam. In Claim Raven's analysis, three in four RA exams were flagged inadequate, the worst share of any condition I looked at, and that exam-quality problem is what drives the 55.2% remand rate. The cases that win document the disease as a system: serologic markers, inflammatory markers, the medication regimen, and a real exacerbation history. Same disease, different paper trail, different outcome.

Related Conditions

Rheumatoid arthritis connects to several other orthopedic pages because the rating logic and proof problems overlap. Compare it with arthritis and gout, the other inflammatory and degenerative joint conditions, and with the joint-specific pages where RA residuals get rated, including knee and shoulder. Fibromyalgia shares the systemic, flare-driven evidence problem where a single exam fails to capture a year of symptoms. Veterans on long-term RA medications should review the secondary conditions tool before assuming the joint rating tells the whole story.

Methodology and Limitations

• Data source: Rating criteria quoted from 38 CFR § 4.71a, DC 5002, including the active-process tiers and the chronic-residual rule. Minimum compensable involvement under DC 5003. Bilateral factor from § 4.26. Secondary service connection from § 3.310. Case law from Allen v. Brown on secondary aggravation.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 505 rheumatoid arthritis cases. Within that subset, outcomes ran 64 granted (12.7%), 279 remanded (55.2%), and 133 denied (26.3%). Of the 332 cases with a C&P adequacy determination, 74.4% had the exam flagged as inadequate, the highest C&P-inadequate share of any condition analyzed, and the remand share is among the highest in the set. The dataset captures overall outcome rather than per-tier (20%/40%/60%/100%) breakdown.
• Classification approach: Diagnostic code definitions drawn from the regulatory text. The two-track structure and the "assign the higher" rule follow DC 5002 directly. Secondary analysis follows § 3.310 and Allen v. Brown.
• Limitations:
• Compensation tiers reflect the rating percentages in DC 5002. Dollar figures adjust annually with COLA.
• The active-versus-inactive determination depends heavily on the quality and currency of the medical record, and application varies at the RO level.
• Selection bias: BVA-level patterns reflect cases that appealed. Most RA claims resolve at the RO level and aren't in any BVA dataset.
• The C&P-inadequacy figure reflects only the 332 RA cases in which adequacy could be assessed, not all 505.
• The medication-secondary chains depend on documented exposure and a sound nexus opinion. They are pathways, not automatic grants.
• These observations reflect patterns from the regulatory text, case law, and BVA decisions. They are not predictions of individual outcomes.